Parkinson's Disease Clinical Trial
Official title:
Rehabilitation of Parkinsonian Gait in Body Weight Support Combined With Treadmill: a Controlled Study
Gait disorders represent disabling symptoms in Parkinson's Disease (PD). The effectiveness of rehabilitation treatment with Body Weight Support Treadmill Training (BWSTT) has been demonstrated in patients with stroke and spinal cord injuries, but limited data is available in PD. The aim of the study is to investigate the efficacy of BWSTT in the rehabilitation of gait in PD patients. Thirty-six PD inpatients were enrolled and performed rehabilitation treatment for 4 weeks, with daily sessions. Subjects were randomly divided into two groups: both groups underwent daily 40-minute sessions of traditional physiokinesitherapy followed by 20-minute sessions of overground gait training (Control group) or BWSTT (BWSTT group). The efficacy of BWSTT was evaluated with clinical scales and Computerized Gait Analysis (CGA). Patients were tested at baseline (T0) and at the end of the 4-week rehabilitation period (T1).
Gait disorders in Parkinson Disease (PD) are due to dopaminergic nigrostriatal pathways
degeneration and represent important components of the disability.
In PD, gait is characterized by a significant reduction of stride length. Inadequate flexion
at the ankle and knee, reduction of heel strike, forward-flexed trunk, reduced arm swing with
asymmetric stride times for lower limbs and significant stride-to-stride variability are
frequently associated.
The efficacy of pharmacological treatment with Levodopa is frequently incomplete and adjuvant
rehabilitation treatment is recommended. Body weight-supported treadmill training (BWSTT)
represents a promising rehabilitative approach for gait impairment in PD. Effectiveness of
BWSTT on gait, balance and motor function has been demonstrated in different neurological
diseases, especially in stroke and spinal cord injury. In PD patients, BWSTT has been tested
in small controlled studies that have suggested a clinically detectable beneficial effect.
BWSTT seems also effective in improving balance in PD. In PD, many data in literature show
how treadmill training, acting as a sensory cue, improves kinetic and kinematic parameters,
studied with computerized gait analysis (CGA) more than physiotherapy alone.
The first report of BWSTT efficacy in gait rehabilitation of PD belongs to Miyai. Ten
patients with PD were enrolled in a cross-over study and treated for 4 consecutive weeks with
BWSTT (20% of unweighting for 12 minutes followed by another 12-min period of 10% of
unweighting) or conventional physical therapy (CPT). The Authors showed that BWSTT was
superior to CPT in improving gait disturbances and disability at the end of the
rehabilitative period. More specifically BWSTT proved superior to CPT in improving UPDRS
scores, gait speed and stride length. The same study group in 2002 evaluated the 6-month
retention of BWSTT in PD. Twenty-four patients with PD were randomized to receive BWSTT (20%
of unweighting for 10 minutes + 10% of unweighting for 10 minutes + 0% of unweighting for an
additional 10-min period) or CPT 3 times/week for 4 consecutive weeks. All patients were
clinically evaluated at baseline and them monthly for 6 months. In this series, gait speed
significantly improved in BWSTT respect to CPT only at month 1, while the improvement in the
stride length was more marked in BWSTT group with respect to CPT and persisted until month 4.
In 2008 Fisher speculated on the possible central mechanism responsible for clinical effects
f BWSTT. Thirty subjects affected by PD were randomly assigned to three groups:
high-intensity group (24 sessions of BWSTT), low-intensity group (24 sessions of CPT),
zero-intensity group (8 weeks of education classes). Again, the high-intensity group improved
the most at the end of treatment period, in particular in gait speed, step length, stride
length and double support. Of note, that in this study a subgroup of patients was also tested
with transcranial magnetic stimulation: in the BWSTT group Authors were able to record a
lengthening of the cortical silent period, postulating that high-intensity training improved
neuronal plasticity in PD, through BDNF and GABA modulation.
Ustinova published the first positive case report on the short-term gait rehabilitation
efficacy of BWSTT delivered to a PD patient with a robotic device (Lokomat - Hocoma Inc.,
Volketswil, Switzerland). The intervention consisted in a 2-week gait training, delivered 3
times per week, with each session lasting 90 to 120 minutes.
Lo conducted a pilot study to assess the efficacy of BWSTT delivered with the Lokomat unit in
reducing frequency of freezing (FOG) of gait in PD. Authors reported a 20% reduction in the
average number of daily episodes of FOG and a 14% improvement in the FOG-questionnaire score.
In 2012 Picelli enrolled 41 PD patients in the first randomised controlled study aimed to
compare the efficacy of BWSTT delivered with a robot-assisted gait training (RAGT - gait
Trainer GT1) to CPT (not focused on gait training) in improving gait in PD. They showed how
RAGT was significantly superior respect to CPT in improving the 6-minute walking test, the
10-meter walking test, stride length, single/double support ratio, Parkinson's Fatigue Scale
and UPDRS score.
In the present study subjects were enrolled among consecutive PD patients hospitalized in the
Neuro-Rehabilitation Unit of the IRCCS Mondino Foundation of Pavia, Italy. Thirty-six
patients affected by Idiopathic PD, according to the UK Brain Bank diagnostic criteria were
included. Subjects were randomly assigned to two groups: 18 PD patients were assigned to the
"BWSTT group" and 18 patients to the "Control group". Before starting treatment, patients of
BWSTT group performed a 20-minute single session of BWSTT in order to test feasibility and
tolerability. Four of them did not tolerate BWSTT: one patient reported an increase in his
pre-existing hip pain, two patients with pre-existing spondyloarthrosis complained of low
back pain, one patient reported that the procedure induced anxious symptoms. These 4 patients
were re-allocated to the control group, so that the final disposition of patients in the two
groups was as follows: 14 patients (8 women and 6 men) in the BWSTT group and 22 patients (10
women and 12 men) in the Control group.
Patients in both groups underwent 5 daily rehabilitation sessions per week for 4 consecutive
weeks. Both groups underwent daily 40-minute sessions of traditional physical therapy (PT)
followed by a 20-minute session of overground gait training (Control group) or of gait
training with BWSTT (BWSTT group).
The traditional PT rehabilitation treatment included passive, active and active-assisted
exercises, according to the methods commonly used (Kabat, Bobath) and previously published
(25, 26) Every 40-minute treatment session consisted in isotonic and isometric exercises for
the major muscles of the limbs and trunk including cardiovascular warm-up exercises (5
minutes), muscle stretching exercises (10 minutes), muscle stretching exercises for
functional purposes (10 minutes), balance training exercises (10 minutes), relaxation
exercises (5 minutes). This protocol was designed in accordance with PD rehabilitation
guidelines and evidences in the literature.
The sessions were conducted on a treadmill with partial weight unload. Specifically, the
patient performed 10-minute treadmill walk with a support corresponding to 20% of his/her own
weight, followed by a 5-minute rest and a second 10-minute session on the treadmill with a
support corresponding to 10% of his/her own weight. In the initial treadmill session, the
starting speed of the treadmill was set to 0.5 km/h, subsequent increments of 0.5 km/h per
minute were added to reach the maximum speed that was comfortably tolerated by the patient.
This latter was used for the entire training period.
All patients were examined by a neurologist with expertise in Movement Disorders at the
beginning of hospitalization (T0) and at the end of the neurorehabilitation period (+4 weeks,
T1). The clinical assessment involved a complete neurological examination and administration
of the following clinical scales, validated for the assessment of the damage/disability:
- for the assessment of PD severity: the Unified Parkinson's Disease Rating Scale, part
III (UPDRS-III);
- for the assessment of functional independence: the Functional Independence Measure
(FIM).
The instrumental assessment of gait was conducted at T0 and T1 by an experienced laboratory
Technician using an Optokinetic Gait Analysis System associated to the software Myolab Clinic
(ELITE, BTS Engineering Milan), composed of six infrared cameras, with a sampling rate of 100
Hz. According to the Davis protocol, twenty-one spherical reflective markers (15mm in
diameter) were applied along the body. Synchronized data acquisition and data processing were
performed by analyzer software (BTS, Milan, Italy). In order to perform kinematic analysis of
gait, patients were instructed to walk at their preferred speed along a 10-meter walkway with
the initial step on the side of disease onset. For each session, the investigators acquired
at least three performances and calculated the mean. In order to obtain the best individual
performance, all recordings were conducted in the ON phase. The sessions were recorded at
5-min intervals to allow complete recovery from fatigue.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Completed |
NCT02939391 -
A Study of KW-6356 in Subjects With Early Parkinson's Disease
|
Phase 2 | |
Terminated |
NCT02924194 -
Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease
|
N/A |